Silencing of hMLH1 expression by aberrant hMLH1 promoter methylation accounts for the majority of sporadic colon cancers with microsatellite instability. We have previously shown hMLH1 silencing is biallelic and actively maintained. To study the mechanism of aberrant hMLH1 methylation, we assayed whether an hMLH1 methylated cell could transfer methylation and silencing to an exogenous hMLH1 promoter in somatic cell hybrids between hMLH1 methylated-silenced and hMLH1 unmethylated-expressing colon cancer cells. Conversely, we assayed whether these hybrids could reactivate expression of initially methylated and silenced hMLH1 alleles. Compellingly, within the hybrids each hMLH1 allele remained unchanged, retaining the expression status of its parental cell of origin. This chromosomal autonomy may not be simply determined by DNA methylation, as it is reasserted after experimentally forced demethylation of all hMLH1 alleles in the hybrids. Con®rming ®ndings included hMLH1 methylated cells being unable to methylate single transferred exogenous hMLH1 expressing chromosomes or transfected hMLH1 reporter constructs. hMLH1 silencing does not conform to either a dominant or recessive model, and is not determined by trans-acting factors diering between hMLH1 expressing or silenced genomes. We posit that hMLH1 methylation is dependent on and maintained by cis chromosomal marks, whose nature remains to be elucidated.
Introduction
Germ line mutation of DNA mismatch repair genes, including the hMLH1 mismatch repair gene, gives rise to the familial colon cancer syndrome of Hereditary Nonpolyposis Colon Cancer in which individuals develop colon, gastric, and endometrial cancers at a young age (Eshleman and Markowitz, 1996; Papadopoulos et al., 1994) . In these cancers, the absence of mismatch repair activity is evidenced by microsatellite instability, which is due to the dramatic acceleration of frame shift mutations in repetitive DNA sequences such as microsatellites. However, microsatellite sequence instability (MSI) colon cancers most commonly develop sporadically in individuals of older age who do not have a family history of colon cancer. We and others have shown that in the majority of such sporadic MSI colon cancers MMR function is inactivated by aberrant methylation and transcriptional silencing of the hMLH1 gene promoter Kane et al., 1997; Veigl et al., 1998) . In cell lines derived from such cancers, treatment with the demethylating agent 5-azacytidine demethylates the hMLH1 promoter and induces re-expression of hMLH1 message and protein (Veigl et al., 1998) . However, we have noted that after washout of 5-azacytidine, hMLH1 expression is again extinguished, suggesting the presence of an active mechanism that in these tumors targets silencing of the hMLH1 promoter. Consistent with this hypothesis we also observed in these tumors the independent methylation of both maternal and paternal hMLH1 alleles (Veigl et al., 1998) . Also supportive of this hypothesis is the demonstration that in Arabidopsis thaliana, widespread promoter hypermethylation and gene silencing can be induced as a downstream consequence of disruption of a chromatin remodeling engine encoded at the ddm 1 locus (Jacobsen and Meyerowitz, 1997; Jeddeloh et al., 1999) .
To test whether an active underlying mechanism indeed maintains aberrant hMLH1 methylation, and whether such a mechanism would be dominant or recessive at the cellular level, we characterized hMLH1 methylated cells that had received either a transfected hMLH1 promoter reporter construct, a transferred exogenous human chromosome 3 bearing wild-type hMLH1, or an entire exogenous human genome by somatic cell fusion to cells bearing unmethylated hMLH1 alleles. In no instance did we observe methylation and silencing of newly introduced hMLH1 promoters, as would be predicted by a dominant cellular defect in methylation maintenance. Conversely, in somatic cell hybrids between cells that silenced hMLH1 and cells that do not, we saw no evidence for demethylation and reactivation of hMLH1 expression, as would be predicted by a recessive defect in methylation maintenance. Rather, in these somatic cell hybrids, all hMLH1 alleles maintained the parental phenotype, either methylated or unmethylated, characteristic of their cells of origin. We conclude that the methylation status of hMLH1 in colon cancer is chromosomal autonomous, and is likely dependent on still unknown cis chromosomal marks.
Results

hMLH1 episomal reporter constructs are not targeted for aberrant methylation
Previous studies have mapped a core promoter region of the hMLH1 gene to between 7184 to 7132 nt relative to the transcription start site (Ito et al., 1999) . Within the extended hMLH1 5'¯anking region, the methylation status of the`C' region (7248 to 7178, relative to the transcription start site) invariably correlates with the hMLH1 expression status, with methylation of this region correlating with hMLH1 promoter silencing (Deng et al., 1999) . To test whether the immediate hMLH1 5'¯ank could be targeted for aberrant methylation, we constructed a reporter vector in which ®re¯y luciferase expression was driven by sequences from 7351 base pairs to +9 base pairs relative to the hMLH1 transcription start, spanning both the hMLH1 core promoter and region`C' ( Figure  1a ). To avoid potential eects due to sites of chromosomal integration, we constructed episomal vectors. Previous studies have demonstrated that eukaryotic cells can methylate episomal DNA (Hsieh, 2000) . The hMLH1 reporter vector was fashioned with an EBV episomal origin of replication, but was free of any other promoter elements or transcription units that could interfere with silencing. In order to maintain the reporter episome in cells, it was cotransfected with à shepherd' construct that expressed EBNA, plus a selectable hygromycin resistance gene, and a control Renilla luciferase gene driven by the pCMV promoter of pCEP4 (Figure 1b) . The reporter and shepherd constructs were cotransfected into RKO colon cancer cells, in which the hMLH1 alleles are fully methylated and silenced, and into SW480 colon cancer cells, which express a normal hMLH1 gene. Pools of stably transfected hygromycin resistant clones were selected and assayed for expression levels of Renilla luciferase from the shepherd construct, and for ®re¯y luciferase Figure 1c , the hMLH1 promoter reporter was expressed equally relative to the control shepherd construct in RKO cells, in which the endogenous hMLH1 alleles are methylated, and in SW480 cells, in which endogenous hMLH1 alleles are fully expressed.
To determine with greater sensitivity if any portion of the hMLH1 promoter sequences in the reporter construct could be methylated in the RKO cells, a modi®ed Hirt method was employed to recover the episomal plasmid DNA from transfected RKO cells. This DNA was then treated with sodium bisul®te in a reaction which converts unmethylated cytosines to uracil, but in which methylated cytosines are protected and unchanged. The hMLH1 promoter sequences were recovered from the bisul®te treated DNA by PCR, and the presence of promoter methylation was determined by sequencing individual clones and examining for any cytosines in CpG dinucleotides that had been protected from conversion to uracil. However, each of 18 individual clones examined proved completely free of any methylation, as shown by bisul®te conversion of 100% of cytosines to uracil across the entire critical`C' region. These results argue that in RKO cells transacting factor(s) are not sucient to cause the aberrant de novo methylation of a virgin hMLH1 promoter, or alternatively, that the hMLH1 promoter fragment employed lacked a region critical for targeting for silencing.
hMLH1 is not targeted for methylation when transferred on an exogenous chromosome 3
To more broadly assay if RKO cells could methylate virgin hMLH1 promoter sequences, chromosome transfer was employed to introduce an exogenous chromosome 3 bearing an hMLH1 allele under the control of its own promoter and in a normal chromosomal environment. Using microcell mediated chromosome transfer (MMCT), a normally expressed hMLH1 allele on the human chromosome 3 donor MCH906.15 was successfully delivered into RKO cells. Following transfer, 10 G418 resistant clones were obtained. Analysis of microsatellite markers D3S1609 and D3S3623 con®rmed that all 10 clones contained the newly transferred chromosome 3 as well as both parental RKO chromosomes 3 (Figure 2a ). However, analysis both by Western blot and immuno¯uorescence for hMLH1 protein determined that at 8 weeks after chromosome transfer, the hMLH1 allele on the newly transferred chromosome 3 was active and well expressed in nine of these MMCT hybrids ( Figure  2b ). In the single clone lacking hMLH1 expression, FISH analysis demonstrated that the transferred chromosome 3 had undergone rearrangement resulting in deletion of the hMLH1 gene locus. Moreover, whereas parental RKO cells showed exclusively methylated hMLH1 promoters, the nine hMLH1 expressing MMCT clones contained both unmethylated as well as methylated hMLH1 promoter DNA when assayed either by methylation speci®c PCR, or by Southern blot detection of two populations of hMLH1 promoter DNA, one resistant and the other susceptible to cutting by the methylation sensitive restriction enzyme HpaII (data not shown).
Thus RKO cells showed no evidence for an activity that could either methylate or silence a virgin hMLH1 gene when introduced on an exogenous chromosome 3. Rather, in these MMCT clones, each hMLH1 locus retained the same phenotype, either methylated or unmethylated, that had existed prior to the chromosome transfer.
Chromosomal autonomy of hMLH1 alleles in somatic cell hybrids
The results of chromosome 3 transfer into RKO cells suggested these cells were unable to silence newly introduced hMLH1 alleles. We therefore considered the possibility that addition of factors from hMLH1 expressing cells might induce reactivation of the hMLH1 alleles in cells in which they had been methylated and silenced. To test this hypothesis, we constructed somatic cell hybrids between colon cancer cells in which hMLH1 alleles were methylated and silenced and colon cancer cells in which hMLH1 alleles were unmethylated and transcribed. As shown in Table  1 , we assayed two independent colon cancer cell lines, Vaco432 and RKO, both of which bear only methylated and silenced hMLH1 alleles. We ®rst attempted to reactivate hMLH1 transcription in these two lines by fusion to HCT116, an MSI line that actively transcribes an hMLH1 transcript bearing a nonsense mutation that does not result in production of productive protein (Papadopoulos et al., 1994) . We con®rmed with RT ± PCR that HCT116 expresses an hMLH1 transcript, but does not express hMLH1 protein as shown by Western blot and immuno¯uor-escence analysis (H Li, unpublished data). Thus detection of hMLH1 protein in any somatic cell hybrids of HCT116 with either RKO or Vaco432 would imply reactivation of a methylated hMLH1 allele derived from either the RKO or Vaco432 parent. However, as shown in Table 2 , no reactivation of a methylated hMLH1 allele was observed in a total of 25 somatic cell hybrids derived from fusion of HCT116 to either RKO or Vaco432 (Table 2 , fusions A and B). Each of these 25 hybrid clones demonstrated the presence of all four parental hMLH1 alleles, as judged by the presence of microsatellite polymorphisms that either¯anked the hMLH1 locus or were located within an hMLH1 intron (D3S1611, Kuismanen et al., 2000) . In the case of hybrids between HCT116 and Vaco432, the presence in the hybrids of at least one Vaco432 methylated hMLH1 allele was further con®rmed by detection of the Vaco432 speci®c G allele of an hMLH1 exon 8 A/G polymorphism (Tables 1 and 2) .
As it was conceivable that hMLH1 reactivation might be selected against in somatic cell hybrids between hMLH1 mutant and hMLH1 methylated genomes, we constructed further somatic cell hybrids in which the methylated Vaco432 and RKO cells were respectively fused to either of two colon cancer cell lines, SW480 or Vaco411, that both express wild-type hMLH1 alleles. These fusion partners were chosen such that in each fusion at least one donor methylated hMLH1 allele could be speci®cally tracked by virtue of a unique value of the exon 8 A/G polymorphism ( Table 2) . We characterized a total of 58 somatic cell hybrids arising from these fusions (Table 2 , fusions C, D, E). In each of these hybrids RT ± PCR demonstrated absence of any transcription arising from the uniquely marked donor methylated hMLH1 allele. The dierent hybrids allowed individual assay for reactivation of each of the Vaco432 methylated hMLH1 alleles, as distinguished by the exon 8 A and G polymorphism, as well as of both RKO methylated alleles as marked by the A allele of the exon 8 polymorphism. We thus conclude that aberrant methylation of hMLH1 in the Vaco432 and RKO colon cancers cannot be reversed simply by complementing these cells with an hMLH1 expressing genome. Moreover, consistent with our results obtained with chromosome transfer, in none of these 58 hybrid clones did we see evidence for methylation and silencing of an hMLH1 allele from an hMLH1 expressing donor genome. Thus, in somatic cell fusions, hMLH1 silencing acted as neither a dominant nor a recessive trait. In a total of 83 individually examined hybrid clones, we consistently observed hMLH1 chromosomal autonomy. That is, hMLH1 alleles in the hybrid clones retained the character of their donor parents. Figure 3 illustrates the speci®c mode of analysis for one of the somatic cell fusions, that between the hMLH1 methylated donor Vaco432 and the hMLH1 expressing Vaco411. D3S1611 genotyping showed that 4 Vaco432xVaco411 hybrids all contained four alleles of hMLH1, two each from both Vaco432 and Vaco411 (Figure 3a) . Moreover, PCR analysis showed each of the clones contained the G allele of the exon 8 A/G polymorphism that tracks one of the Vaco432 methylated hMLH1 alleles (Figure 3c , Tables 1 and  2 ). Immuno¯uorescence and Western blot analysis detected hMLH1 protein expression, indicating that hMLH1 alleles from Vaco411 were not silenced ( Figure  3b ). However, RT ± PCR showed no expression derived from the G allele that was donated by the hMLH1 (Figure 3d and Table 2 ).
Chromosomal autonomy is not reversed by 5-azacytidine
One potential explanation for the inability to reactivate the Vaco432 or RKO methylated hMLH1 alleles would be that methylation of the Vaco432 and RKO alleles provides a persistent cis mark that itself blocks reactivation of these alleles by fusion to an hMLH1 expressing genome. However, we had previously shown that, whereas the demethylating agent 5-azacytidine can reactivate hMLH1 expression in Vaco432 and RKO cells, following 5-azacytidine washout the reactivated hMLH1 allele was again silenced. Accordingly, we asked whether a methylated genome that was reactivated by 5-azacytidine demethylation could be rescued and maintained in a permanently active state by fusion to an hMLH1 expressing genome. To most directly ask this question, we treated with 5-azacytidine somatic cell hybrids of either Vaco432 or RKO cells with HCT116 (which transcribe a mutant hMLH1 that is not detected by antibody assays). Both Vaco432 parental cells and ®ve clones of HCT116xVaco432 hybrids were treated with 5-azacytidine on days 2 and 5. As shown in Figure 4 , induction of wild-type hMLH1 protein expression arising from demethylation of Vaco432 alleles was easily detected on Western blot at day 9. However, washout of the 5-azacytidine again resulted in silencing of hMLH1 expression in both Vaco432 cells as well as in the HCT116xVaco432 hybrid cells. Identical results were also seen on 5-azacytidine treatment and washout of hybrids derived from RKO and HCT116. In other words, 5-azacytidine did not reverse chromosomal autonomy. The RKO and Vaco432 derived chromosomes appear to be marked for hMLH1 silencing by a mechanism that is additional to simply the methylation of the hMLH1 alleles. This mechanism is not reversed by forcing hMLH1 re-expression with 5-azacytidine, even in the presence in the same hybrid nucleus with additional hMLH1 expressing alleles. These observations suggest the presence on the RKO and Vaco432 hMLH1 alleles of a cis mark that directs methylation of the hMLH1 alleles, but that is additional to and not simply derived from the existing methylation state of the alleles.
Discussion
These studies demonstrate that methylation and silencing of the hMLH1 gene in colon cancer is chromosomal autonomous. hMLH1 methylated colon cancers showed no ability to transfer methylation to a new hMLH1 promoter whether that promoter was introduced as an hMLH1 promoter fragment, as part of an exogenous hMLH1 expressing chromosome 3, or as part of a complete genome from an hMLH1 expressing cell. Conversely, fusion with an hMLH1 expressing genome could not induce demethylation and reactivation of the silenced hMLH1 alleles. Thus the mechanism of hMLH1 silencing does not conform to a simple dominant or recessive model, and does not appear to primarily be determined by trans acting factors expressed by the hMLH1 expressing or silenced cell. In this regard, the mechanism underlying Figure 4 Resilencing of hMLH1 protein expression following 5-azacytidine treatment of HCT116xVaco432 fusion clones. Shown is Western blot analysis of hMLH1 expression in parental Vaco432 and HCT116xVaco432 fusion clones following treatment with 5-azacytidine. Cells were treated with 5-azacytidine on days 2 and 5, followed by drug washout on day 6. Maximal hMLH1 protein expression was detected on day 9 in both Vaco432 and HCT116xVaco432 hybrid cells. However following withdrawal of 5-azacytidine, hybrid cells had by day 23 reverted to absence of expression for hMLH1, as was also substantially the case for the parental Vaco432 hMLH1 silencing in cancer would appear to diverge from the seemingly similar phenotype described in Arabidopsis thaliana, in which widespread promoter methylation and gene silencing can be consequent to inactivation of a presumed trans acting chromatin remodeling engine encoded at the ddm1 locus (Jacobsen and Meyerowitz, 1997; Jeddeloh et al., 1999) . Rather than being determined by trans acting factors, hMLH1 silencing demonstrates chromosomal autonomy, in which the methylation and expression state of the hMLH1 promoters in hybrid environments remains that of the parental donors. Moreover, the signal directing silencing of hMLH1 must consist of factors additional to just the methylation state of the allele, as reactivation of a Vaco432 or RKO hMLH1 allele with 5-azacytidine is followed by resilencing of the allele after 5-azacytidine washout. This is true even when the silenced hMLH1 alleles are reactivated in somatic cell hybrids that bear an unmethylated and constitutively transcribing hMLH1 allele. These observations argue that hMLH1 silencing of the Vaco432 and RKO alleles is actively maintained, and argue against any`hit and run' model in which hMLH1 methylation is simply induced by a stochastic event in cellular metabolism, or by an aberrant cellular factor lost during cancer progression, or by an environmental exposure, such as to toxins described as inducing heterochromatinization (Lee et al., 1995) . Rather we favor the hypothesis that a still uncharacterized cis mark is likely involved in directing the methylation and silencing of hMLH1 alleles in the colon cancers in which it is observed. Such cis marks have for example been implicated in the aberrant methylation of the VHL renal cancer gene (Kuzmin et al., 1999) . However, given our ®nding that hMLH1 methylation is often biallelic (Veigl et al., 1998) , we would need to infer that this genomic locus must be particularly vulnerable to the generation of such a putative cis mark. The molecular nature of such a mark remains speculative, though one model that has been proposed would involve methylation centers that are outside of the boarders of the gene ultimately targeted for promoter methylation and silencing (Issa, 2000) . Alternatively, studies of the mechanism underlying imprinting at the murine H19 locus provide one model from a non-cancer context that demonstrates that the presence or absence of a binding site for a speci®c protein, the CTCF factor, can in fact determine the methylation and gene expression pattern across an entire genomic region (Hark et al., 2000) . In hMLH1 methylated cells we have not detected any mutation after sequencing 1 kb of the hMLH1 5' ank. However, aberrant methylation and silencing of the hMLH1 locus is clearly the initiating event in most sporadic MSI colon cancers, and is perhaps the most common example of aberrant methylation directly contributing to human cancer . Moreover, aberrant methylation at other genetic loci has also been implicated as being a pathogenetic event in other human malignancies Grady et al., 2000; Robertson and Junes, 2000) . Thus, further studies to elucidate the underlying mechanism of hMLH1 methylation in the models we describe here will certainly be of future importance.
Materials and methods
Constructs
To construct the episomal reporter vector, the pCEP4 plasmid was digested with SexAI and BstEII and religated to delete the EBNA gene, then digested again with NruI and BglII to delete the hygromycin r gene and CMV promoter, and religated. The hMLH1 promoter was ampli®ed using the primers: 5'-CATGCCATGGAAGCTTTCAGCAGAGGCA-CACAAGCC and 5'-CATGCCATGGCTCGAGCGCCA-GAAGAGCCAAGGAAAC, then ligated into the modi®ed vector. Finally, the ®re¯y luciferase gene was ligated downstream of the hMLH1 promoter. For the control shepherd vector, Renilla luciferase gene was ligated into the unmodi®ed pCEP4 vector.
Cell culture
Vaco cell were cultured as previously described (Veigl et al., 1998; Markowitz et al., 1995; Willson et al., 1987) . HCT116 and SW480 were obtained from the American Type Culture Collection, and RKO was originally from M Brattain (Roswell Cancer Institute, Bualo, NY, USA).
Microcell mediated chromosome transfer
The MMCT donor cell line, MCH906.15, containing human chromosome 3 has been described (Cheng et al., 1998) . MMCT was performed as described (Casey et al., 1993) .
Somatic cell fusion
Cell fusion partners were ®rst individually transfected with either plasmid pRC-CMV or pBABE-Puro using Fugene6 (Roche) and selected for neomycin resistance or puromycin resistance respectively. Two fusion partners were fused and hybrid clones were selected as described before (Geiser et al., 1989) .
5-Azacytidine treatment
The treatment was performed as described previously (Veigl et al., 1998) . Brie¯y, cells were treated for 24 h on day 2 and day 5 with 5-azacytidine (Sigma) at 1.5 mg/ml. The medium was changed 24 h after addition of the 5-azacytidine (i.e., on day 3 and day 6).
Western analysis
Approximately 10 7 cells were lysed in UBI cell lysis buer (50 mM Tris.HCl (pH 7.4)/1 mM EGTA/1% Nonidet P-40/ 0.25% sodium deoxycholate/150 mM NaCl). Equal amounts of protein were subjected to SDS polyacrylamide gel electrophoresis and then transferred to a PVDF nylon membrane (Millipore), which was probed with 2 mg/ml mouse anti-hMLH1 monoclonal antibody (PharMingen). Immune complexes were visualized with ECL+Plus Western blotting detection kit (Amersham) after incubation with horseradish peroxidase-coupled secondary antibody (Santa Cruz).
Amplification and sequencing of hMLH1
Genomic DNA was obtained and ampli®ed as described (Veigl et al., 1998) . RNA was puri®ed using RNeasy total Mini kit (Qiagen). Final products were treated with DNasel (Roche). The cDNA for hMLH1 was ampli®ed by using the Titan RT ± PCR system (Roche). Reverse transcription, PCR and cycle sequencing was carried out as described (Veigl et al., 1998) .
Genotyping D3S1611, D3S1609, D3S3623 primer sets were from Research Genetics. D3S1611 is located in intron 12 of hMLH1, while D3S1609 and D3S3623¯ank the gene on either side within 6-centiMorgan distance.
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P end-labeled PCR product was separated on a 6% denaturing gel, followed by phosphoimager detection (Wiesner et al., 2001) .
Methylation assays
Bisul®te Treatment and Sequencing of DNA. Episomal vector DNA was puri®ed following the protocol as described (Arad, 1998) . Sodium bisul®te treatment to convert unmethylated cytosines to thymidines was performed similarly as described (Grady et al., 2001) . Methyl-speci®c PCR conditions and primers were as described (Grady et al., 2001) . For analysis of the hMLH1 promoter in episomal vector, vector speci®c primers were used: F1 5'-TTTGTAAAAGTAATT-GTTTTAGGAATTAG and R1: 5'-CATAATAAAAAAAACCATCCAACCT. PCR conditions were: 958C 45 s, 528C 1 min, 728C 45 s; 35 cycles.
